12.1 estimated diagnosed patients with diabetes, up 1 mm from 2000. Costs of diabetes in 2002 estimated at $135 b, up from $98 b in 1997, the last …
Diabetes Care, March 2003
American Diabetes Association Position Statement -
Economic Costs of Diabetes in the US in 2002
Summary of Key Stats
1 Diabetes now fifth leading cause by death in the US
2 121 estimated diagnosed patients with diabetes, up 1 mm from
2000
3 Costs of diabetes in 2002 estimated at 135 b, up from 98 b in
1997, the last time they did these stats
Direct medical expenditures estimated at 918 billion
232 b for diabetes care
246 b for chronic complications associated with diabetes
441 b for excess prevalence of general medical conditions
160 b of 865 b of total medical expense associated with
diabetes - 185
Per capita medical expenditures totaled 13,243 for people
with diabetes and 2,560 for people without diabetes When
adjusting for differences in age, sex, and race/ethnicity
between the population with and without diabetes, people
with diabetes had medical expenditures that were 24
times higher than expenditures
that would be incurred by
the same group in the absence of diabetes
4 The estimated 132 billion cost likely underestimates the true
burden of diabetes because it omits intangibles, such as pain
and suffering, care provided by nonpaid caregivers, and several
areas of health care spending where people with diabetes
probably use services at higher rates than people without
diabetes eg, dental care, optometry care, and the use of
licensed dietitians
5 In addition, the cost estimate excludes undiagnosed cases of
diabetes
6 Health care spending in 2002 for people with diabetes is more
than double what spending would be without diabetes
7 Diabetes imposes a substantial cost burden to society and, in
particular, to those individuals with diabetes and their
families
8 Eliminating or reducing the health problems caused by diabetes
through factors such as better access to preventive care, more
widespread diagnosis, more intensive disease management, and the
advent of new medical technologies
could significantly improve
the quality of life for people with diabetes and their families
while at the same time potentially reducing national
expenditures for health care services and increasing
productivity in the US economy
This report was not underwritten by any specific industry participants
Support for the study was provided by ADA, the National Institute of
Diabetes and Digestive and Kidney Diseases, and the ADA Industry Advisory
Council
Source:shapeup.org
